U.S. medical devices developer Trice Medical has raised $18.3 million in a Series C extension financing round.
Trice Medical plans to use the funds to extend its worldwide commercialization efforts for mi-eye 2 and mi-ultra and to advance the development of the company’s minimally invasive product portfolio.
Charter Capital Partners and Municipal Employees’ Retirement System led the round with participation from Safeguard Scientifics, Inc., HealthQuest Capital, BioStar Ventures and Smith & Nephew.
Trice Medical has bagged a total of $42.6 million in over five funding rounds.